Comparative Pharmacology
Head-to-head clinical analysis: CAPOZIDE 50 15 versus TRANDOLAPRIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CAPOZIDE 50 15 versus TRANDOLAPRIL.
CAPOZIDE 50/15 vs TRANDOLAPRIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CAPOZIDE 50/15 combines captopril (angiotensin-converting enzyme inhibitor) and hydrochlorothiazide (thiazide diuretic). Captopril inhibits ACE, reducing angiotensin II formation, decreasing aldosterone secretion, and lowering blood pressure. Hydrochlorothiazide increases sodium and water excretion by inhibiting the Na+/Cl- cotransporter in distal convoluted tubules.
Trandolapril is a prodrug that is hydrolyzed to its active metabolite trandolaprilat, which inhibits angiotensin-converting enzyme (ACE), blocking the conversion of angiotensin I to angiotensin II. This reduces vasoconstriction, aldosterone secretion, and sodium reabsorption, leading to decreased blood pressure and preload/afterload reduction.
Oral, 1 tablet (captopril 50 mg / hydrochlorothiazide 15 mg) once daily. May increase to 2 tablets daily in divided doses if needed.
1–2 mg orally once daily; maximum 4 mg once daily.
None Documented
None Documented
Clinical Note
moderateTrandolapril + Etacrynic acid
"The risk or severity of adverse effects can be increased when Trandolapril is combined with Etacrynic acid."
Clinical Note
moderateTrandolapril + Furosemide
"The risk or severity of adverse effects can be increased when Trandolapril is combined with Furosemide."
Clinical Note
moderateTrandolapril + Bumetanide
"The risk or severity of adverse effects can be increased when Trandolapril is combined with Bumetanide."
Clinical Note
moderateCaptopril: terminal half-life ~2 hours (in patients with normal renal function; prolonged in renal impairment to 21-36 hours). Hydrochlorothiazide: half-life 6-15 hours (mean ~9 hours; prolonged in renal impairment). Clinical context: dosing interval affected by renal function.
Trandolapril: 6 hours; Trandolaprilat: 24 hours (terminal); effective half-life for ACE inhibition: ~24 hours allowing once-daily dosing
Captopril: renal excretion of unchanged drug and metabolites, primarily in urine (60-75%), with ~20% as unchanged captopril; small amount in feces (5-10%). Hydrochlorothiazide: renal excretion (95% unchanged), <5% via biliary/fecal.
Renal: 33% (as trandolaprilat); Fecal: 66% (as trandolapril and trandolaprilat); Biliary: minimal
Category C
Category D/X
ACE Inhibitor and Diuretic Combination
ACE Inhibitor
Trandolapril + Benzydamine
"The risk or severity of adverse effects can be increased when Trandolapril is combined with Benzydamine."